OBJECTIVES: Perform the measurement of quality of life related to health in patients with rheumatoid arthritis in Colombia, who are receiving biological therapy. METHODS: In 252 patients with rheumatoid arthritis receiving biologic therapy, in December 2010 to May 2011 - established the quality of life reported by the patient by applying the Health Assessment Questionnaire (HAQ), and its correlation with the level of disease activity scale as disease Activity Score (DAS28). The analysis was supplemented by linear regression of HAQ variable depending on other variables of interest: DAS28, population characteristics, time of use, treatment received and adverse events (AE). RESULTS: Linear regression showed that three variables (DAS28 and adverse events) are significant in explaining variations in the quality of life of patients with RA treated with biological therapy in Colombia. We found that 63,3% of patients with a DAS28 <3.2 have less of one point in the HAQ score, while in patients with DAS28>3.2, the 71.97% exceeded the HAQ score limit in one point. The AE is and important variable in determining the quality of life of patients, although on average only 15.6% of patients with RA showed AE regardless of biological treatment used. There were no significant differences by treatment type, age and gender on the population studied. CONCLUSIONS: Quality of life related to health (HAQ level) varies significantly depending on the state of disease activity (DAS28) in patients treated with biological therapy.